

浏览全部资源
扫码关注微信
复旦大学附属肿瘤医院病理科,复旦大学上海医学院肿瘤学系,上海 200032
Received:26 March 2023,
Revised:2023-07-03,
Published:30 September 2023
移动端阅览
Jing WEI, Yaqi HE, Tian XUE, et al. Clinicopathological analysis of DLBCL/HGBL with
Jing WEI, Yaqi HE, Tian XUE, et al. Clinicopathological analysis of DLBCL/HGBL with
背景与目的:
伴
MYC
、
BCL
2和
BCL
6基因重排的弥漫性大B细胞淋巴瘤/高级别B细胞淋巴瘤(diffuse large B-cell lymphoma/high-grade B-cell lymphoma,DLBCL/HGBL)又称三重打击淋巴瘤(triple-hit lymphoma,THL),其发病率低且文献报道较少,人们对其缺乏充分认识。本研究旨在探讨THL的临床病理学特征及患者预后。
方法:
收集复旦大学附属肿瘤医院病理科2016年6月—2021年12月诊断的THL病例10例,回顾性分析其临床特征,采用H-E染色观察其组织病理学特征,采用免疫组织化学法分析其免疫表型,采用荧光原位杂交(fluorescence
in situ
hybridization,FISH)法检测
MYC
、
BCL
2和
BCL
6基因重排,采用EB病毒编码RNA(Epstein-Barr virus-encoded RNA,EBER)原位杂交法检测判断EB病毒的感染状态。
结果:
10例THL患者中,男性4例,女性6例。中位年龄54岁(43~80岁)。其中2例发生在淋巴结,6例发生在结外器官,其余2例结内外均受累。临床分期Ⅲ/Ⅳ期4例(40%),Ⅰ/Ⅱ期6例(60%)。40%(4/10)的患者国际预后指数(international prognostic index,IPI)评分≥3分。50%(4/8)的患者有骨髓侵犯。2例(20%)有B症状。40%(4/10)的患者有乙肝病毒既往感染史。显微镜下观察5例呈非特指DLBCL(DLBCL
not otherwise specified,DLBCL-NOS)形态,2例兼具DLBCL与伯基特淋巴瘤特征,1例呈母细胞样形态,其余2例因组织挤压严重无法准确分类。免疫组织化学染色显示,80%为生发中心B细胞(germinal center B-cell,GCB)型,20%为非GCB(non-GCB)型;78%(7/9)为MYC/BCL2双表达,BCL6阳性率为80%,Ki-67增殖指数均≥80%。FISH检测显示,10例均同时有
MYC
、
BCL
2和
BCL
6基因重排。EBER原位杂交均呈阴性。除1例手术切除病灶后未化疗外,9例均接受系统治疗。10例患者的总生存期为2.0 ~ 55.5个月,中位总生存期为16.8个月。1年总生存率为68.6%,其中Ⅰ/Ⅱ期患者的1年总生存率100%,Ⅲ/Ⅳ期患者为25%。
结论:
THL好发于中老年人,以结外器官受累更常见,是一组形态学表现多样、以GCB型为主并常伴有MYC/BCL2双表达的侵袭性B细胞淋巴瘤。本研究患者中临床分期Ⅰ/Ⅱ期占多数且预后较好,因此及早甄别THL对于及时干预、改善预后具有重要临床意义。
Background and purpose:
Diffuse large B-cell lymphoma/high-grade B-cell lymphoma (DLBCL/HGBL) with gene rearrangement of
MYC
BCL
2 and
BCL
6
also known as triple-hit lymphoma (THL)
has a low incidence and relevant literature is limited. Thus comprehensive and sufficient understanding is lacking. The purpose of this study was to explore the clinicopathological features and prognosis of this rare disease.
Methods:
Ten cases of THL diagnosed in Department of Pathology
Fudan University Shanghai Cancer Center from June 2016 to December 2021 were collected. Clinical features were analyzed retrospectively. Histopathological features were observed using H-E stain. Immunophenotype was analyzed by immunohistochemistry. The rearrangement of
MYC
BCL
2 and
BCL
6 genes was detected by fluorescence
in situ
hybridization (FISH)
and Epstein-Barr virus (EBV) infection was detected by
in situ
hybridization using EBV-encoded RNA (EBER).
Results:
Of the 10 cases
4 cases were male and 6 cases were female. The median age was 54 years (43-80 years). Two cases occurred in lymph nodes
6 cases involved extranodal organs
and both lymph nodes and extranodal organs were involved in the other 2 cases. There were 4 cases (40%) with clinical stage Ⅲ/Ⅳ disease and 6 cases (60%) with clinical stage Ⅰ/Ⅱ disease. 40% (4/10) patients had international prognostic index (IPI) score ≥3. 50% (4/8) patients had bone marrow invasion. Two (20%) cases had B symptoms. 40% (4/10) patients had a history of hepatitis B virus infection. Five cases had the morphology of DLBCL
not otherwise specified (DLBCL-NOS); Two cases showed morphological features intermediate both DLBCL and Burkitt lymphoma; One case had a blastoid cytomorphology
and the other 2 cases failed to be classified accurately because of serious crushing artifacts of the tissue. Immunophenotypically
80% of the cases were of germinal center B-cell (GCB) type and 20% were of non-GCB type. MYC/BCL2 double expression accounted for 78% (7/9)
BCL6 positivity was found in 80% of t
he total cases
and the Ki-67 proliferation index was ≥80% in all cases. FISH showed that all 10 cases had
MYC
BCL
2 and
BCL
6 gene translocation rearrangement. EBV infection was consistently absent. All except one case received systemic treatment. The overall survival was 2.0-55.5 months (median
16.8 months)
and 1-year overall survival rate was 68.6%. The 1-year overall survival rates of patients with stage Ⅰ/Ⅱ disease and stage Ⅲ/Ⅳ disease were 100% and 25% respectively.
Conclusion:
THL mainly affects middle-aged and elderly patients
which occured more frequently in extranodal organs
and it is characterized by GCB immunophenotype and MYC/BCL2 double expression. A considerable number of patients have a clinical stage of Ⅰ/Ⅱ disease and a better prognosis in the current series
indicating that early identification of THL is of great importance for timely intervention and improving the prognosis.
SWERDLOW S H , CAMPO E , HARRIS N L , et al . World Health Organization classification of tumours of haematopoietic and lymphoid tissues [M ] . Lyon : IARC Press , 2017 .
ALAGGIO R , AMADOR C , ANAGNOSTOPOULOS I , et al . The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms [J ] . Leukemia , 2022 , 36 ( 7 ): 1720 - 1748 . DOI: 10.1038/s41375-022-01620-2 http://doi.org/10.1038/s41375-022-01620-2
PETRICH A M , GANDHI M , JOVANOVIC B , et al . Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis [J ] . Blood , 2014 , 124 ( 15 ): 2354 - 2361 . DOI: 10.1182/blood-2014-05-578963 http://doi.org/10.1182/blood-2014-05-578963
SARKOZY C , TRAVERSE-GLEHEN A , COIFFIER B . Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas [J ] . Lancet Oncol , 2015 , 16 ( 15 ): e555 -e567. DOI: 10.1016/S1470-2045(15)00005-4 http://doi.org/10.1016/S1470-2045(15)00005-4
HOWLETT C , SNEDECOR S J , LANDSBURG D J , et al . Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis [J ] . Br J Haematol , 2015 , 170 ( 4 ): 504 - 514 . DOI: 10.1111/bjh.2015.170.issue-4 http://doi.org/10.1111/bjh.2015.170.issue-4 https://onlinelibrary.wiley.com/toc/13652141/170/4 https://onlinelibrary.wiley.com/toc/13652141/170/4
OKI Y , NOORANI M , LIN P , et al . Double hit lymphoma: the MD Anderson Cancer Center clinical experience [J ] . Br J Haematol , 2014 , 166 ( 6 ): 891 - 901 . DOI: 10.1111/bjh.2014.166.issue-6 http://doi.org/10.1111/bjh.2014.166.issue-6 https://onlinelibrary.wiley.com/toc/13652141/166/6 https://onlinelibrary.wiley.com/toc/13652141/166/6
ROSENTHAL A , YOUNES A . High grade B-cell lymphoma with rearrangements of MYC and BCL 2 and/or BCL 6: double hit and triple hit lymphomas and double expressing lymphoma [J ] . Blood Rev , 2017 , 31 ( 2 ): 37 - 42 .
PEMMARAJU N , GILL J , GUPTA S , et al . Triple-hit lymphoma [J ] . Proc (Bayl Univ Med Cent) , 2014 , 27 ( 2 ): 125 - 127 . DOI: 10.1080/08998280.2014.11929083 http://doi.org/10.1080/08998280.2014.11929083
BACHER U , HAFERLACH T , ALPERMANN T , et al . Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms [J ] . Genes Chromosomes Cancer , 2011 , 50 ( 1 ): 43 - 50 . DOI: 10.1002/gcc.v50:1 http://doi.org/10.1002/gcc.v50:1 http://doi.wiley.com/10.1002/gcc.v50%3A1 http://doi.wiley.com/10.1002/gcc.v50%3A1
TOMITA N , TOKUNAKA M , NAKAMURA N , et al . Clinicopathological features of lymphoma/leukemia patients carrying both BCL 2 and MYC translocations [J ] . Haematologica , 2009 , 94 ( 7 ): 935 - 943 . DOI: 10.3324/haematol.2008.005355 http://doi.org/10.3324/haematol.2008.005355 http://www.haematologica.org/cgi/doi/10.3324/haematol.2008.005355 http://www.haematologica.org/cgi/doi/10.3324/haematol.2008.005355
MOTLLÓ C , GRAU J , JUNCÀ J , et al . Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma [J ] . Cancer Genet Cytogenet , 2010 , 203 ( 2 ): 328 - 332 . DOI: 10.1016/j.cancergencyto.2010.08.018 http://doi.org/10.1016/j.cancergencyto.2010.08.018 https://linkinghub.elsevier.com/retrieve/pii/S0165460810004814 https://linkinghub.elsevier.com/retrieve/pii/S0165460810004814
ELDESSOUKI T , HANLEY K , HAMADEH F , et al . “Triple hit” lymphomas: a retrospective cytology case series of an uncommon high grade B-cell malignancy with C - MYC , BCL -2 and BCL -6 rearrangements [J ] . Diagn Cytopathol , 2018 , 46 ( 9 ): 807 - 811 . DOI: 10.1002/dc.v46.9 http://doi.org/10.1002/dc.v46.9 https://onlinelibrary.wiley.com/toc/10970339/46/9 https://onlinelibrary.wiley.com/toc/10970339/46/9
WANG W , HU S M , LU X Y , et al . Triple-hit B-cell lymphoma with MYC , BCL 2, and BCL 6 translocations/rearrangements: clinicopathologic features of 11 cases [J ] . Am J Surg Pathol , 2015 , 39 ( 8 ): 1132 - 1139 . DOI: 10.1097/PAS.0000000000000434 http://doi.org/10.1097/PAS.0000000000000434 https://journals.lww.com/00000478-201508000-00014 https://journals.lww.com/00000478-201508000-00014
HANS C P , WEISENBURGER D D , GREINER T C , et al . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J ] . Blood , 2004 , 103 ( 1 ): 275 - 282 . DOI: 10.1182/blood-2003-05-1545 http://doi.org/10.1182/blood-2003-05-1545
李敏 , 张秋露 , 赵炜 , 等 . 伴 MYC 、 BCL 2和(或) BCL 6重排的高级别B细胞淋巴瘤在弥漫大B细胞淋巴瘤中的发生率 [J ] . 中华血液学杂志 , 2021 , 42 ( 2 ): 124 - 128 .
LI M , ZHANG Q L , ZHAO W , et al . Incidence of high-grade B-cell lymphoma with MYC , BCL 2, and/or BCL 6 rearrangements in diffuse large B-cell lymphoma [J ] . Chin J Hematol , 2021 , 42 ( 2 ): 124 - 128 .
HUANG W T , MEDEIROS L J , LIN P , et al . MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas [J ] . Mod Pathol , 2018 , 31 ( 9 ): 1470 - 1478 . DOI: 10.1038/s41379-018-0067-x http://doi.org/10.1038/s41379-018-0067-x https://linkinghub.elsevier.com/retrieve/pii/S0893395222011565 https://linkinghub.elsevier.com/retrieve/pii/S0893395222011565
ZHANG J J , WENG Z P , HUANG Y H , et al . High-grade B-cell lymphoma with MYC , BCL 2, and/or BCL 6 translocations/rearrangements: clinicopathologic features of 51 cases in a single institution of South China [J ] . Am J Surg Pathol , 2020 , 44 ( 12 ): 1602 - 1611 . DOI: 10.1097/PAS.0000000000001577 http://doi.org/10.1097/PAS.0000000000001577 https://journals.lww.com/10.1097/PAS.0000000000001577 https://journals.lww.com/10.1097/PAS.0000000000001577
TRAN J , VICKERS A , PONCE C P , et al . Triple-hit lymphoma of the cavernous sinus [J ] . Can J Ophthalmol , 2019 , 54 ( 2 ): e61 -e66. DOI: 10.1016/j.jcjo.2018.06.007 http://doi.org/10.1016/j.jcjo.2018.06.007
EFSTATHOPOULOU A , GHIELMINI M , ZUCCA E . MYC/BCL2/BCL6 triple hit lymphoma of the pericardium: a case report and review of the literature [J ] . J Cancer Res Clin Oncol , 2020 , 146 ( 9 ): 2435 - 2438 . DOI: 10.1007/s00432-020-03137-6 http://doi.org/10.1007/s00432-020-03137-6
ZHOU X , PAN H X , YANG P , et al . Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma [J ] . BMC Cancer , 2019 , 19 ( 1 ): 477 . DOI: 10.1186/s12885-019-5718-x http://doi.org/10.1186/s12885-019-5718-x
ABE S K , INOUE M , SAWADA N , et al . Hepatitis B and C virus infection and risk of lymphoid malignancies: a population-based cohort study (JPHC Study) [J ] . Cancer Epidemiol , 2015 , 39 ( 4 ): 562 - 566 . DOI: 10.1016/j.canep.2015.06.002 http://doi.org/10.1016/j.canep.2015.06.002
ENGELS E A , CHO E R , JEE S H . Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study [J ] . Lancet Oncol , 2010 , 11 ( 9 ): 827 - 834 . DOI: 10.1016/S1470-2045(10)70167-4 http://doi.org/10.1016/S1470-2045(10)70167-4
REN W , YE X , SU H , et al . Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma [J ] . Blood , 2018 ; 131 ( 24 ): 2670 - 2681 . DOI: 10.1182/blood-2017-11-817601 http://doi.org/10.1182/blood-2017-11-817601
DENG L J , SONG Y Q , YOUNG K H , et al . Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin [J ] . Oncotarget , 2015 , 6 ( 28 ): 25061 - 25073 . DOI: 10.18632/oncotarget.4677 http://doi.org/10.18632/oncotarget.4677
AUKEMA S M , KREUZ M , KOHLER C W , et al . Biological characterization of adult MYC -translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma [J ] . Haematologica , 2014 , 99 ( 4 ): 726 - 735 . DOI: 10.3324/haematol.2013.091827 http://doi.org/10.3324/haematol.2013.091827 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.091827 http://www.haematologica.org/cgi/doi/10.3324/haematol.2013.091827
SWERDLOW S H . Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC [J ] . Hematology Am Soc Hematol Educ Program , 2014 , 2014 ( 1 ): 90 - 99 .
SCOTT D W , KING R L , STAIGER A M , et al . High-grade B-cell lymphoma with MYC and BCL 2 and/or BCL 6 rearrangements with diffuse large B-cell lymphoma morphology [J ] . Blood , 2018 , 131 ( 18 ): 2060 - 2064 . DOI: 10.1182/blood-2017-12-820605 http://doi.org/10.1182/blood-2017-12-820605 https://ashpublications.org/blood/article/131/18/2060/36718/Highgrade-Bcell-lymphoma-with-MYC-and-BCL2-andor https://ashpublications.org/blood/article/131/18/2060/36718/Highgrade-Bcell-lymphoma-with-MYC-and-BCL2-andor
PEDERSEN M Ø , GANG A O , POULSEN T S , et al . Double-hit BCL 2/ MYC translocations in a consecutive cohort of patients with large B-cell lymphoma-a single centre’s experience [J ] . Eur J Haematol , 2012 , 89 ( 1 ): 63 - 71 . DOI: 10.1111/ejh.2012.89.issue-1 http://doi.org/10.1111/ejh.2012.89.issue-1 http://doi.wiley.com/10.1111/ejh.2012.89.issue-1 http://doi.wiley.com/10.1111/ejh.2012.89.issue-1
ZIEPERT M , LAZZI S , SANTI R , et al . A 70% cut-off for MYC protein expression in diffuse large B-cell lymphoma identifies a high-risk group of patients [J ] . Haematologica , 2020 , 105 ( 11 ): 2667 - 2670 . DOI: 10.3324/haematol.2019.235556 http://doi.org/10.3324/haematol.2019.235556 https://haematologica.org/article/view/9647 https://haematologica.org/article/view/9647
CUCCUINI W , BRIERE J , MOUNIER N , et al . MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation [J ] . Blood , 2012 , 119 ( 20 ): 4619 - 4624 . DOI: 10.1182/blood-2012-01-406033 http://doi.org/10.1182/blood-2012-01-406033 https://ashpublications.org/blood/article/119/20/4619/29963/MYC-diffuse-large-Bcell-lymphoma-is-not-salvaged https://ashpublications.org/blood/article/119/20/4619/29963/MYC-diffuse-large-Bcell-lymphoma-is-not-salvaged
KÜHNL A , CUNNINGHAM D , COUNSELL N , et al . Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14V21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial [J ] . Ann Oncol , 2017 , 28 ( 7 ): 1540 - 1546 . DOI: 10.1093/annonc/mdx128 http://doi.org/10.1093/annonc/mdx128
GREEN T M , YOUNG K H , VISCO C , et al . Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [J ] . J Clin Oncol , 2012 , 30 ( 28 ): 3460 - 3467 .
GROSS T G , HALE G A , HE W S , et al . Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents [J ] . Biol Blood Marrow Transplant , 2010 , 16 ( 2 ): 223 - 230 . DOI: 10.1016/j.bbmt.2009.09.021 http://doi.org/10.1016/j.bbmt.2009.09.021 https://linkinghub.elsevier.com/retrieve/pii/S1083879109004443 https://linkinghub.elsevier.com/retrieve/pii/S1083879109004443
KANG J N , ZHANG Y Z , DING S , et al . Modified conditioning regimen with chidamide and high-dose rituximab for triple-hit lymphoma [J ] . J Cell Mol Med , 2021 , 25 ( 22 ): 10770 - 10773 . DOI: 10.1111/jcmm.16999 http://doi.org/10.1111/jcmm.16999
SNUDERL M , KOLMAN O K , CHEN Y B , et al . B-cell lymphomas with concurrent IGH- BCL 2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma [J ] . Am J Surg Pathol , 2010 , 34 ( 3 ): 327 - 340 . DOI: 10.1097/PAS.0b013e3181cd3aeb http://doi.org/10.1097/PAS.0b013e3181cd3aeb https://journals.lww.com/00000478-201003000-00004 https://journals.lww.com/00000478-201003000-00004
VALERA A , LÓPEZ-GUILLERMO A , CARDESA-SALZMANN T , et al . MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy [J ] . Haematologica , 2013 , 98 ( 10 ): 1554 - 1562 . DOI: 10.3324/haematol.2013.086173 http://doi.org/10.3324/haematol.2013.086173
TZANKOV A , XU-MONETTE Z Y , GERHARD M , et al . Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP [J ] . Mod Pathol , 2014 , 27 ( 7 ): 958 - 971 . DOI: 10.1038/modpathol.2013.214 http://doi.org/10.1038/modpathol.2013.214 https://linkinghub.elsevier.com/retrieve/pii/S0893395222018798 https://linkinghub.elsevier.com/retrieve/pii/S0893395222018798
ADAMS T , FUCHS D , SHADOAN P K , et al . Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC , BCL 6 and BCL 2 loci [J ] . Cancer Genet , 2018 , 222 - 223 : 25 - 31 .
0
Views
3553
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621